国际妇产科学杂志

国际妇产科学杂志 ›› 2012, Vol. 39 ›› Issue (2): 152-157.

• 综述 • 上一篇    下一篇

卵巢癌靶向治疗的研究进展


俞 弋,徐丛剑   

  1. 200011 上海，复旦大学附属妇产科医院
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2012-04-15 发布日期:2012-04-15

Targeted Therapies Advances in Ovarian Cancer

YU Yi，XU Cong-jian   

  1. Obstetric and Gynecology Hospital，Fudan University，Shanghai 200011，China
  • Received:1900-01-01 Revised:1900-01-01 Published:2012-04-15 Online:2012-04-15

PDF (PC)

4886

被引次数

21

摘要： 女性生殖器官恶性肿瘤中，卵巢癌病死率居第1位。尽管手术及化疗技术有所改进，但是复发率和耐药性仍居高不下。靶向治疗成为治疗卵巢癌的一种有效手段。靶向治疗能够增强对肿瘤细胞的杀伤力，减少对正常组织的损伤，目前逐步应用于卵巢癌的临床治疗，且与传统治疗方法相比显示出优势。从分子靶向药物治疗和靶向基因治疗两个方面对近年来卵巢癌靶向治疗的研究现况、治疗应用进行总结以及展望。

关键词: 卵巢肿瘤, 抗体, 单克隆, 基因疗法, 遗传载体, 信号传导, 分子靶向治疗, PARP抑制剂

Abstract: Ovarian cancer is the leading cause of death from gynecological cancer. Although some advances in surgical and chemotherapeutic strategies have been made， there still remains a significant risk for recurrence and resistance to therapy. Targeted therapy become a effective method against ovarian cancer， which could improve the ability to kill cancer cells and to reduce the damage to normal tissues. Targeted therapy has gradually applied to clinical treatment and shown an advantage to tranditional ones. This paper review targeted therapies in ovarian cancer in form of molecular targeted and gene targeted， in order to know about the current situation and the prospective research of the treatment in ovarian cancer.

Key words: Ovarian neoplasmas, Antibodies, monoclonal, Gene therapy, Genetic vectors, Signal transduction, PARP inhibitor